| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.09 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.094 | 0.09 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.054 | 0.09 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.084 | 0.1 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.1 |